1. Case history {#s1}
===============

A 78-year-old female with vocational school education was admitted for a second hospitalization after a seven-year history of depressive symptoms, a two-year history of reduced physical activity, and a one-year history of memory loss. Initially, in 2008 after being frightened by the results of a urine test for a urinary tract infection, she became depressed and anorexic. She was diagnosed at a local general hospital with major depression (without psychotic symptoms) and treated with paroxetine and alprazolam for two months until the symptoms remitted. In 2012, while providing nursing care for her younger sister who had lung cancer, her depressive symptoms recurred and she made two suicide attempts by overdose with alprazolam. This led to a one-month psychiatric hospitalization that included treatment with sertraline, mirtazapine, and electroconvulsive therapy (ECT); after discharge she was able to do housework and grocery shopping. However, starting in June 2013, without any obvious trigger her activity level gradually decreased. She became uncommunicative and was unwilling to leave her home, neither watching TV nor doing any housework. She spent all of her time in bed, so her 82-year-old husband (who had hypertension and chronic bronchitis) had to assist with her eating and routine self-care. Starting in 2014 she reported experiencing short-term memory loss which made her forget what she had eaten for breakfast or what she had just read in the newspaper. She was initially treated as an outpatient, though most of the outpatient visits were with the husband alone because he was physically unable to regularly transport her to the outpatient department. She was prescribed a variety of medications including venlafaxine, citalopram, mianserin, Deanxit (a combined preparation of flupentixol and melitracen), mirtazapine, amisulpride, and quetiapine. Over 18 months of outpatient treatment there was no significant improvement, so she was readmitted to hospital.

On admission the patient reported a history of hypertension which had been controlled for the previous four years by taking 1-2 tablets per day of a combination anti-hypertensive (each tablet included reserpine, hydrochlorothiazide, dihydralazine, and promethazine), but she had no other significant personal or family history of illness. Physical examination revealed excoriated skin with infected lesions on her limbs and face due to poor hygiene and scratching. On mental status exam she was conscious, but she appeared apathetic, repeatedly asking to be allowed to go to sleep during the interview. She was inattentive, responding passively to questions with answers that were devoid of meaning. She was disoriented to time and space and had apparent memory lapses. She reported intermittent auditory hallucinations, saying that she could hear her brother speaking in the doorway.

Further laboratory and neuropsychological examinations had the following results: (a) no abnormal blood chemistry results; (b) an abnormal electroencephalogram (EEG) (shown in [Figure 1](#fig1){ref-type="fig"}, Panel A), with the δ domain power increased and the α domain power decreased; (c) abnormal magnetic resonance imaging (MRI) test (shown in [Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}), indicating ischemia in the right basal ganglia area and bilateral frontal lobe, hippocampus atrophy, and diffuse conical atrophy; (d) mild depression and anxiety as rated by the Hamilton Rating Scale for Depression (HAMD)^\[[@B1]\]^ (score=15), and the Hamilton Anxiety Rating Scale (HAMA)^\[[@B2]\]^ (score=8); and (c) decline in cognitive function as indicated by results of the Mini Mental State Examination (MMSE)^\[[@B3]\]^ (score=21), the Montreal Cognitive Assessment Scale (MoCA)^\[[@B4]\]^ (score=11), the Wechsler Adult Intelligence Scale-Revised in Chinese (WASI-RC)^\[[@B5]\]^ (IQ score=64), the revised Chinese version of the Wechsler Memory (WMSRC)^\[[@B6]\]^ (score=47), and supplemental tests that revealed difficulties in delayed memory, visual recognition, and verbal fluency.

![Electroencephalogram (EEG). (A) Abnormal EEG on admission: prompting θ, δ domain power increased, and α domain power decreased. (B) EEG returns to normal after 6 weeks of treatment: θ domain power in occipitoparietal region increased and α domain power normalized](sap-28-02-109-g002){#fig1}

![Cranial magnetic resonance imaging: right basal ganglia area and bilateral frontal area have punctiform ischemia (A is T1 weighted image; B is T2 weighted image)](sap-28-02-109-g003){#fig2}

![Hippocampus magnetic resonance imaging: hippocampus atrophy and brain atrophy (A is coronal view, B is sagittal view)](sap-28-02-109-g004){#fig3}

The admitting diagnosis was major depression and possible dementia (which had to be ruled out). On admission she continued on the medications she had been taking as an outpatient: citalopram 20 mg/d, mirtazapine 15 mg/d, quetiapine 25 mg/d, memantine 5 m g/d, oxiracetam 400 mg bid (to promote recognition), and lorazepam 0.5 mg qn (to improve sleep). Because reserpine, the anti-hypertensive medication she had been taking for four years, is a monoamine depletion agent which may exacerbate depression, we changed it to amlodipine 5 mg/d to control her blood pressure. While an inpatient she also participated in group cognitive behavioral therapy, family counseling, and art and music activities. There was no significant improvement after 2 weeks of treatment: her drowsiness, limited speech, lack of interest, and aversion to activity persisted. So we modified the treatment plan to the following: sertraline 50 mg/d, memantine 10 mg/d, rivastigmine 3 mg bid, and aripiprazole 2.5 mg/d. After 6 weeks of this new treatment regimen her test results indicated improvement in the depressive and anxiety symptoms: HAMD=9; HAMA=6. Her EEG had returned to normal, as shown in Panel B of [Figure 1](#fig1){ref-type="fig"}, the fragmentary auditory hallucinations had faded, and she had become somewhat more socially interactive. However, her cognitive problems with attention and executive functioning had only improved slightly: MMSE=22; and MoCA=16.

At the time of hospital discharge, 8 weeks after admission, her discharge diagnosis was treatment resistant depression and the discharge medications were amlodipine 5 mg/d, sertraline 100 mg/d, and rivastigmine 3 mg bid. After she returned home, we also arranged for the delivery of daily meals and for regular home visits from community workers. She attended monthly outpatient follow-up visits, but there was no further improvement in her depressive and cognitive symptoms. Seven months after discharge she became increasingly fatigued and experienced many falls; this resulted in admission to the surgery department of a general hospital where she was diagnosed with advanced breast cancer and started on chemotherapy. At that point her sertraline and rivastigmine were stopped and she was changed to trazadone 50 mg qn (to improve sleep). Her depressive and cognitive symptoms subsequently increased.

2. Discussion {#s2}
=============

Prior to the current admission the patient had been treated with several different antidepressants at an adequate dose for at least 6 weeks, but none of these courses of treatment were effective, so she met criteria for treatment resistant depression. Unlike her previous depressive episodes, the current episode included physical weakness and apathy, transient hallucinatory phenomena, and marked cognitive decline. Based on these findings and the diffuse conical atrophy and hippocampal atrophy seen on brain imaging, we concluded that the patient also met diagnostic criteria for Alzheimer\'s disease(AD).^\[[@B8]\]^ The diagnostic difficulty was to determine whether she had two concurrent illnesses or a single illness that included both prominent affective and prominent cognitive features. And if it was a single disorder, which one?

Considering her prior episodes of depression, our initial diagnosis was depression with impaired cognitive functioning. Epidemiological studies^\[[@B9]\]^ report that 30- 50% of patients with depression have concurrent cognitive dysfunction; in elderly depressed patients the cognitive dysfunction can include impairments in memory, attention, information processing, and executive functioning.^\[[@B10]\]^ If the cognitive dysfunction in depressed elderly is improved with antidepressant treatment, this is considered \'pseudo dementia\'^\[[@B11]\]^ and, thus, is differentiated from AD. However, if residual cognitive symptoms remain after effective antidepressant treatment - as occurred in this case - these cognitive symptoms can either be considered residual symptoms of depression or, alternatively, the behavioral and cognitive manifestations of a separate disorder (dementia). In this patient, the presence of transient auditory hallucinations and other symptoms which were not present in her prior episodes of depression suggest an underlying organic brain disease; if this is the case, the current episode of depression could be an indicator of prodromal AD.^\[[@B12]\]^

Two additional factors further complicated the diagnosis. First, the patient had used reserpine (which depletes monoamines and is often a cause of depression) as a treatment for hypertension for several years prior to admission. As is true for the majority of such cases, ^\[[@B13]\]^ the depressive and anxiety symptoms improved after stopping the reserpine (and giving antidepressants). The failure to see substantial concurrent cognitive improvement after stopping reserpine could be to several reasons: there may be an independent dementing process; the long-term use of reserpine may have caused permanent brain damage; or cognitive improvement may take much longer than improvement in depression because it takes a long time to fully restore depleted monoamine reserves. Another complicating issue is the patient\'s lack of family support, something essential in the management of geriatric depression.^\[[@B14],\ [@B15]\]^ Having no children, her elderly husband was her sole care-giver; her infrequent visits to the outpatient department made it impossible to manage her complicated condition appropriately and to observe the gradual onset of cognitive impairment.

Currently popular treatments for patients suffering from depression with cognitive dysfunction include medication combined with psychological and physical treatments such as repetitive transcranial magnetic stimulation (rTMS) and modified electroconvulsive therapy (MECT).^\[[@B16]\]^ In this case, inpatient admission was required to re-adjust her medications and to provide psychotherapy and opportunities for increasing her social activities. After 8 weeks of treatment her depressive and anxiety symptoms had improved significantly and her indifference and social inactivity improved slightly, but there was relatively little improvement in her cognitive impairments. We conclude that long-term follow-up, probably for two-to- three years, will be needed to definitively determine the primary cause (or causes) of her cognitive symptoms.

Many elderly individuals who seek help from health services suffer from both depression and cognitive impairment. There are several important lessons that this case highlights. (a) Elderly patients with underlying cognitive impairment who experience a depressive episode are more likely to develop dementia^\[[@B17]\]^ and have a poor response to medication.^\[[@B18]\]^ This complicates the diagnosis and management of such patients and, thus, necessitates both a detailed physical exam and a thorough neuropsychological evaluation prior to the initiation of treatment. (b) Longitudinal observation of the course of illness may be needed to determine the correct diagnosis. A two-year longitudinal study of 201 non-demented elderly patients who experienced depression with cognitive dysfunction found that 50 (25%) recovered, 30 (15%) developed dementia, and 121 (60%) maintained some cognitive dysfunction.^\[[@B19]\]^ (c) Clinicians who treat elderly patients must be aware of the cognitive effects of commonly used psychoactive drugs, and they must be up-to-date on the potential affective and cognitive side-effects of the full range of medications used to treat the physical illnesses experienced by elderly individuals. A research study in the United States estimated that there are 5.6 to 8.0 million people over the age of 65 who misuse medications that often cause cognitive impairment, including benzodiazepines, anticholinergics, opioids, analgesics, hypnotics, and antipsychotics.^\[[@B20]\]^ (d) Family and social support is important to the quality of life and social functioning of all elderly individuals, but it is even more important for elderly persons with depression or dementia. These individuals need substantial help in managing their condition beyond what can be provided by the health care system. Part of the clinical assessment of such individuals should include an assessment of the types of social support available to the patient. Subsequent treatment planning should include provision of educational and psychological support to primary care-givers, and, when necessary, involvement of community-based social services to assist when the available family resources are insufficient.
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